AU2018351007B2 - Treatment of ovarian cancer with anti-CD47 and anti-PD-L1 - Google Patents

Treatment of ovarian cancer with anti-CD47 and anti-PD-L1 Download PDF

Info

Publication number
AU2018351007B2
AU2018351007B2 AU2018351007A AU2018351007A AU2018351007B2 AU 2018351007 B2 AU2018351007 B2 AU 2018351007B2 AU 2018351007 A AU2018351007 A AU 2018351007A AU 2018351007 A AU2018351007 A AU 2018351007A AU 2018351007 B2 AU2018351007 B2 AU 2018351007B2
Authority
AU
Australia
Prior art keywords
antibody
ser
val
tumor
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018351007A
Other languages
English (en)
Other versions
AU2018351007A1 (en
Inventor
Mark Ping Chao
Chris Hidemi Mizufune TAKIMOTO
Jens-Peter VOLKMER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Forty Seven LLC
Original Assignee
Forty Seven LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Forty Seven LLC filed Critical Forty Seven LLC
Publication of AU2018351007A1 publication Critical patent/AU2018351007A1/en
Application granted granted Critical
Publication of AU2018351007B2 publication Critical patent/AU2018351007B2/en
Assigned to Forty Seven, LLC reassignment Forty Seven, LLC Request to Amend Deed and Register Assignors: FORTY SEVEN, INC.
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU2018351007A 2017-10-18 2018-10-18 Treatment of ovarian cancer with anti-CD47 and anti-PD-L1 Active AU2018351007B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762574073P 2017-10-18 2017-10-18
US62/574,073 2017-10-18
PCT/US2018/056442 WO2019079549A1 (en) 2017-10-18 2018-10-18 TREATMENT OF OVARY CANCER BY ANTI-CD47 AND ANTI-PD-L1

Publications (2)

Publication Number Publication Date
AU2018351007A1 AU2018351007A1 (en) 2020-05-21
AU2018351007B2 true AU2018351007B2 (en) 2024-05-16

Family

ID=64402251

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2018351007A Active AU2018351007B2 (en) 2017-10-18 2018-10-18 Treatment of ovarian cancer with anti-CD47 and anti-PD-L1

Country Status (12)

Country Link
US (1) US20210047416A1 (enExample)
EP (2) EP4194470A1 (enExample)
JP (3) JP7308190B2 (enExample)
KR (1) KR20200070341A (enExample)
CN (1) CN111315783A (enExample)
AU (1) AU2018351007B2 (enExample)
CA (1) CA3078430A1 (enExample)
ES (1) ES2938652T3 (enExample)
PL (1) PL3697819T3 (enExample)
PT (1) PT3697819T (enExample)
SI (1) SI3697819T1 (enExample)
WO (1) WO2019079549A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114716552B (zh) 2016-01-11 2024-05-24 四十七公司 人源化、小鼠或嵌合抗cd47单克隆抗体
CN111247172B (zh) 2017-10-18 2023-11-14 四十七公司 基于抗cd47剂的卵巢癌疗法
EP4129336B1 (en) 2018-02-12 2025-05-07 Forty Seven, LLC Anti-cd47 agent-based treatment of cd20-positive cancer
EP3969484A4 (en) * 2019-05-17 2023-07-05 Nanjing GenScript Biotech Co., Ltd. ANTI-CD47/ANTI-PD-L1 MULTIPLE ANTIGEN BINDING PROTEINS AND METHODS OF USE
US11702474B2 (en) 2019-12-17 2023-07-18 Pfizer Inc. Antibodies specific for CD47, PD-L1, and uses thereof
CN120437288A (zh) * 2019-12-24 2025-08-08 正大天晴药业集团南京顺欣制药有限公司 治疗卵巢癌的药物组合
WO2021170082A1 (zh) * 2020-02-28 2021-09-02 南京圣和药业股份有限公司 抗cd47/抗pd-l1抗体及其应用
CN116670289A (zh) * 2021-01-08 2023-08-29 北京韩美药品有限公司 抗pd-l1/抗cd47天然抗体结构样异源二聚体形式双特异抗体及其制备

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017127707A1 (en) * 2016-01-21 2017-07-27 The Board Of Trustees Of The Leland Stanford Junior University Treatment of cancer with combinations of immunoregulatory agents

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2616010T3 (es) 2010-05-14 2017-06-09 The Board Of Trustees Of The Leland Stanford Junior University Anticuerpos monoclonales humanizados y quiméricos a CD47
AU2014238105B2 (en) 2013-03-15 2018-11-15 The Board Of Trustees Of The Leland Stanford Junior University Methods for achieving therapeutically effective doses of anti-CD47 agents
CA2961774C (en) * 2014-10-07 2023-05-23 Immunomedics, Inc. Neoadjuvant use of antibody-drug conjugates
TWI595006B (zh) * 2014-12-09 2017-08-11 禮納特神經系統科學公司 抗ｐｄ－１抗體類和使用彼等之方法
WO2017019767A1 (en) * 2015-07-27 2017-02-02 Myosotis, Llc Inhibition of CXCL12 in Cancer Immunotherapy
CA2998644A1 (en) * 2015-09-18 2017-03-23 Arch Oncology, Inc. Therapeutic cd47 antibodies
US20190290759A1 (en) * 2015-12-28 2019-09-26 Syndax Pharmaceuticals, Inc. Combination of hdac inhibitor and anti-pd-l1 antibody for treatment of ovarian cancer

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017127707A1 (en) * 2016-01-21 2017-07-27 The Board Of Trustees Of The Leland Stanford Junior University Treatment of cancer with combinations of immunoregulatory agents

Also Published As

Publication number Publication date
JP7474827B2 (ja) 2024-04-25
PT3697819T (pt) 2023-02-20
ES2938652T3 (es) 2023-04-13
EP4194470A1 (en) 2023-06-14
JP2023014162A (ja) 2023-01-26
US20210047416A1 (en) 2021-02-18
KR20200070341A (ko) 2020-06-17
EP3697819A1 (en) 2020-08-26
AU2018351007A1 (en) 2020-05-21
WO2019079549A1 (en) 2019-04-25
CN111315783A (zh) 2020-06-19
EP3697819B1 (en) 2022-11-16
SI3697819T1 (sl) 2023-01-31
JP2024024121A (ja) 2024-02-21
CA3078430A1 (en) 2019-04-25
JP7308190B2 (ja) 2023-07-13
PL3697819T3 (pl) 2023-03-06
JP2021500336A (ja) 2021-01-07

Similar Documents

Publication Publication Date Title
US20250066473A1 (en) Treatment of cancer with combinations of immunoregulatory agents
AU2018351007B2 (en) Treatment of ovarian cancer with anti-CD47 and anti-PD-L1
US20240218077A1 (en) Anti-cd47 agent-based treatment of cd20-positive cancer
US12030944B2 (en) Enhanced depletion of targeted cells with CD47 blockade and an immune costimulatory agonist
AU2018351006B2 (en) Anti-CD47 agent-based ovarian cancer therapy
HK40092424A (en) Treatment of ovarian cancer with anti-cd47 and anti-pd-l1
HK40036031B (en) Treatment of ovarian cancer with anti-cd47 and anti-pd-l1
HK40036031A (en) Treatment of ovarian cancer with anti-cd47 and anti-pd-l1
US20250367289A1 (en) Dosage regimen for a combination therapy consisting oftcr-engineered t-cells in combination with a pd-1 axis binding antagonist
HK40077720A (en) Treatment of cancer with combinations of immunoregulatory agents
HK40032879A (en) Treatment of ovarian cancer with anti-cd47 and anti-pd-l1
US9868792B2 (en) Methods of enhancing anti-tumor immunity by administering antibodies to the CCRL2 chemerin receptor
HK40043124B (en) Anti-cancer regimen using anti-cd47 and anti-cd20 antibodies
HK40043124A (en) Anti-cancer regimen using anti-cd47 and anti-cd20 antibodies

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
HB Alteration of name in register

Owner name: FORTY SEVEN, LLC

Free format text: FORMER NAME(S): FORTY SEVEN, INC.